ACCEL Lite: IRONMAN – Randomized Trial of Intravenous Ferric Derisomaltose in HFrEF

<p class="MsoNormal"><span style= "font-family: 'Times New Roman',serif; mso-no-proof: yes;">Iron deficiency is very common in patients with heart failure, affecting between one third to a half of all patients. IRONMAN will help determine if treatment with intravenous iron can help patients feel better, and reduce the risk of being hospitalized for heart failure or dying.</span></p> <p class="MsoNormal"><span style= "font-family: 'Times New Roman',serif; mso-no-proof: yes;"> </span><span style="font-family: 'Times New Roman',serif;">In this interview, <span style="mso-no-proof: yes;">Professor Paul Kalra MD, FRCP and Roger S. Blumenthal MD, FACC</span> discuss <span style="mso-no-proof: yes;">IRONMAN – Randomized Trial of Intravenous Ferric Derisomaltose in HFrEF.</span></span></p> <p class="MsoNormal"><span style= "font-family: 'Times New Roman',serif;"> </span><a href= "https://itunes.apple.com/us/podcast/eagles-eye-view-your-weekly-cv-update-from-acc-org/id1274635046">Subscribe on Apple</a> <span class="MsoHyperlink">Podcasts</span> <span style="font-family: 'Times New Roman',serif;">|</span> <a href= "https://play.google.com/music/listen#/ps/I6dtkumvaipematzgzmbph2koiq"> Subscribe on Google Play</a> <span class="MsoHyperlink">|</span> <a href= "http://www.acc.org/education-and-meetings/products-and-resources/accel-audio"> Subscribe to ACCEL</a></p>